Archive: Feb 2021

  1. Dr. Savage reports back from the webinar held by the European Society of Sexual Medicine 19th & 20th February 21 – Testosterone Treatment and Prostate Cancer

    Leave a Comment

    A study in Germany in 2016 showed that 83% of doctors felt that testosterone treatment may cause an increased rate of prostate cancer despite the fact that there is no evidence to suggest this.

    There is no association between the level of testosterone in the blood stream and the incidence of prostate cancer, if anything the suggestion is that in patients at time of diagnosis of prostate cancer that those with the lowest level of testosterone are likely to be more aggressive cancers.

    Testosterone therapy does noPost Radical Prostatectomy. Highlights from European Society of Sexual Medicine.t change the incidence of prostate cancer, most experts in the world now agree that testosterone treatment can be started after treatment for prostate cancer with people varying in how cautious their approach is. EAU guidelines in 2019 state that the patient should be at least after initial treatment and that the patient should have a Gleason <8 score, however, interestingly a recent study showed that in patients who had been treated for prostate cancer and followed up after 6 years and who were suffering from testosterone deficiency the untreated group of patients had a much higher biochemical recurrence of their prostate cancer than in those who had been on testosterone treatment.

  2. Dr. Savage “attended” the webinar held by the European Society of Sexual Medicine – Conference 19th & 20th February 2021 and reports back on the following highlights – Diabetes and Testosterone Deficiency

    Leave a Comment

    Professor A. Morgantaler from Boston, one of the world’s leading Andrologists presented 3 impressive studies about the effects of testosterone treatment in pre-diabetes and type 2 diabetes.

    First study an 8-year observational study by Lead Clinician Yasin, on pre-diabetics with starting testosterone levels < 12nnmol/l in the un-treated group 40% became full blown diabetics over the 8 year period, whereas those treated with long acting testosterone injection Nebido 1000 mg, none became diabetic.http://diabetesERECTILE DYSFUNCTION

    The second study was an 11-year observational study, lead by Lead Clinician Haider, this as of 356 men who had type 2 diabetes and starting testosterones <12 nnmol/l, in the group of patients who were treated with long acting Nebido 1000 mg there was a remission of diabetes in 34% of patients who had complete remission and were able to come off all diabetic medication.

    The third study, Australian RCT study led by Professor Gary Wittert was a 2-year, large study of over 1000 patients, 88 in the treatment group having established type 2 diabetes and 355 pre-diabetes, there was a 40% reduction in the number of patients progressing to diabetes in comparison with those patients treated by intensive life style advice through the Weight Watchers programme.Testosterone deficiency in Type 2 diabetes

    Screening for hypogonadism, there are now many leading endocrine and diabetes organisations which are suggesting screening all type 2 diabetics, those men with erectile dysfunction, obese men with waist size greater than 102cms.http://obesityCase Study

    Remember, it has been found that 42% of diabetics have testosterone levels <12nnmol/l with symptoms of testosterone deficiency.

    Hypogonadism is the commonest cause of osteoporosis and low trauma fracture in men, so all of these patients should be screened.

    Metabolic syndrome doubles the risk of stroke and cardiovascular disease. It is the disease of the 21st century and will lead to an estimated prevalence of type 2 diabetes of 20% by 2030.

    Many authors have stated that the type 2 diabetes epidemic will bankrupt the NHS.